Rheumatoid arthritis treatment drug

Tocilizumab-Atlizumab Overview Introduction of Tocilizumab Tocilizumab, also known as atlizumab, is a recombinant humanized, anti-human monoclonal antibody mAb of the immunoglobulin G1κ subclass directed against soluble and membrane-bound interleukin-6 IL-6 receptor IL-6R which plays an important role in immune response and is implicated rheumatoid arthritis treatment drug the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.

It was developed by Hoffmann-La Roche and Chugai.

ízületek fájnak a kisujj közelében agyag ízületi fájdalmak áttekintésére

Tocilizumab is now licensed in the EU for use alone or in combination with disease-modifying anti-rheumatic drugs DMARDs to treat adult patients with moderate to severely active rheumatoid arthritis RAchildren over 2 y of age with the systemic form of juvenile idiopathic arthritis sJIA or children over 2 y of age with the polyarticular form of juvenile idiopathic arthritis pJIA. Mechanism of Action of Tocilizumab IL-6 is a multifunctional cytokine that plays an important role in both acute and chronic inflammatory responses.

serdülők térdízületi kezelése a porc típusú regenerálódási képessége

Consequently, the dysregulated or persistent production of IL-6 can lead to the development of inflammatory disorders. Tocilizumab targets the IL-6 receptor subunit alpha IL-6Rαand its mechanism of action has been described in detail in previous reviews.

a lumbosakrális ízületi gyulladása szoptató anyák ízületi fájdalmai

Briefly, Tocilizumab targets both membrane-bound and soluble IL-6Rα, which prevents the binding of IL-6 to both the IL-6R and the signal transducer glycoprotein complex and results in turn in inhibition of the downstream classic signaling and trans-signaling cascades involving the Janus-activated kinase-signal transducer and activator of transcription JAK-STAT pathway.

Through this mechanism, Tocilizumab decreases the circulating levels of neutrophils, neutrophil infiltration into inflamed joints, circulation of myeloid dendritic cells, monocyte levels, serum macrophage migration inhibitory factor levels, and levels of T helper 17 Th17 cells, while increasing regulatory T cells. Tocilizumab also induces regulatory B-cell expansion, decreases B-cell hyperactivity, and decreases the number of peripheral memory B cells.

kenőcs a boka ízületének sprainjeire glükózamin és kondroitin étkezés előtt vagy után

Hasznosmegbeszélések